Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRx0518 plus Pembrolizumab in Refractory Solid Tumors
NCT03637803Phase 2Terminated
- Sponsor
- 4D Pharma plc
- Start
- Jan 2019
- Primary completion
- May 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRx0518 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer and 1 more, sponsored by 4D Pharma plc. Primary endpoints: Safety and tolerability of MRx0518 in combination with pembrolizumab up to 2 years and Clinical benefit of MRx0518 in combination with pembrolizumab up to 2 years. Started Jan 2019; status: terminated.
02
Drugs
MRx0518
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)bladder cancermelanoma
Beyond the preview
Go deeper on NCT03637803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637803.